X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (25951) 25951
Dissertation (331) 331
Book Chapter (252) 252
Conference Proceeding (43) 43
Publication (38) 38
Government Document (19) 19
Magazine Article (13) 13
Book / eBook (8) 8
Paper (2) 2
Web Resource (2) 2
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
mapk (10077) 10077
animals (9916) 9916
humans (9162) 9162
p38 mapk (5762) 5762
biochemistry & molecular biology (5340) 5340
phosphorylation (5317) 5317
signal transduction (5131) 5131
apoptosis (5088) 5088
mice (5062) 5062
cell biology (5003) 5003
expression (4629) 4629
activation (4554) 4554
male (3661) 3661
kinases (3461) 3461
proteins (3356) 3356
map kinase (3167) 3167
oncology (2948) 2948
p38 mitogen-activated protein kinases - metabolism (2919) 2919
rats (2873) 2873
mitogen-activated protein kinases - metabolism (2848) 2848
pharmacology & pharmacy (2843) 2843
inflammation (2795) 2795
female (2581) 2581
activated protein-kinase (2511) 2511
cancer (2499) 2499
oxidative stress (2476) 2476
cells, cultured (2404) 2404
cell line, tumor (2358) 2358
gene expression (2303) 2303
protein kinases (2261) 2261
nf-kappa-b (2191) 2191
inhibition (2158) 2158
signal transduction - drug effects (2140) 2140
cell line (2101) 2101
cells (1985) 1985
analysis (1966) 1966
gene-expression (1958) 1958
map kinase signaling system - drug effects (1881) 1881
neurosciences (1828) 1828
immunology (1712) 1712
apoptosis - drug effects (1661) 1661
proliferation (1613) 1613
pathway (1605) 1605
research (1575) 1575
research article (1491) 1491
erk (1487) 1487
map kinase signaling system (1460) 1460
pathways (1442) 1442
nf-κb (1425) 1425
in-vitro (1406) 1406
cytokines (1394) 1394
kinase (1387) 1387
mitogens (1380) 1380
biology (1374) 1374
growth (1370) 1370
cell proliferation (1353) 1353
extracellular signal-regulated kinase (1349) 1349
mapk pathway (1322) 1322
mapks (1293) 1293
medicine, research & experimental (1282) 1282
extracellular signal-regulated map kinases - metabolism (1272) 1272
blotting, western (1267) 1267
nf-kappa b (1259) 1259
mitogen-activated protein kinase (1249) 1249
medicine (1216) 1216
p38 (1207) 1207
signaling (1204) 1204
nf-kappa b - metabolism (1200) 1200
enzyme activation (1190) 1190
rats, sprague-dawley (1176) 1176
enzyme inhibitors - pharmacology (1170) 1170
biophysics (1167) 1167
protein (1159) 1159
phosphorylation - drug effects (1154) 1154
differentiation (1140) 1140
physiological aspects (1117) 1117
dose-response relationship, drug (1103) 1103
signaling pathways (1097) 1097
physiology (1078) 1078
multidisciplinary sciences (1077) 1077
protein-kinase (1074) 1074
cell proliferation - drug effects (1062) 1062
reactive oxygen species - metabolism (1060) 1060
health aspects (1052) 1052
mutation (1043) 1043
signal transduction - physiology (1042) 1042
rodents (1035) 1035
cell cycle (1020) 1020
cell survival - drug effects (1016) 1016
mice, inbred c57bl (1010) 1010
macrophages (996) 996
jnk (995) 995
mitogen-activated protein kinase 1 - metabolism (994) 994
genetic aspects (966) 966
akt (962) 962
up-regulation (958) 958
toxicology (944) 944
stress (943) 943
mechanisms (942) 942
induction (941) 941
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (25456) 25456
Chinese (836) 836
Japanese (203) 203
Korean (145) 145
French (109) 109
Portuguese (48) 48
German (44) 44
Spanish (40) 40
Polish (17) 17
Czech (10) 10
Turkish (7) 7
Russian (6) 6
Norwegian (4) 4
Croatian (2) 2
Slovak (2) 2
Swedish (2) 2
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Oncogene, ISSN 0950-9232, 03/2001, Volume 20, Issue 13, pp. 1653 - 1660
Journal Article
Pain medicine (Malden, Mass.), ISSN 1526-2375, 01/2014, Volume 15, Issue 1, pp. 93 - 110
Objective The pathobiology of prostate cancer (PCa)‐induced bone pain (PCIBP) has both inflammatory and neuropathic components. Previously, we showed that... 
Nerve Growth Factor (NGF) | Phospho‐p38 Mitogen‐Activated Protein Kinase (MAPK) | Prostate Cancer‐Induced Bone Pain (PCIBP) | Angiotensin II | Angiotensin II Type 2 Receptor (AT2R) | Phospho‐p44/p42 MAPK | Phospho-p44/p42 MAPK | Nerve growth factor (NGF) | Prostate cancer-induced bone pain (PCIBP) | Phospho-p38 Mitogen-activated protein kinase (MAPK) | p42 MAPK | MECHANICAL ALLODYNIA | ACTIVATED PROTEIN-KINASE | AT RECEPTOR | ROOT GANGLION NEURONS | P38 MAPK | Phospho-p38 Mitogen-Activated Protein Kinase (MAPK) | NERVE GROWTH-FACTOR | NEUROPATHIC PAIN | MEDICINE, GENERAL & INTERNAL | NEURITE OUTGROWTH | NG108-15 CELLS | Angiotensin II Type 2 Receptor (ATR) | Phospho-p44 | PRIMARY SENSORY NEURONS | Prostate Cancer-Induced Bone Pain (PCIBP) | Analgesics - pharmacology | Injections, Intravenous | Nerve Growth Factor - analysis | Rats, Wistar | Receptor, Angiotensin, Type 2 - physiology | Bone Neoplasms - secondary | Receptor, Angiotensin, Type 2 - drug effects | Male | Cell Line, Tumor - transplantation | Angiotensin II Type 2 Receptor Blockers - pharmacology | Dose-Response Relationship, Drug | RNA, Messenger - biosynthesis | Lumbosacral Region | Mitogen-Activated Protein Kinases - analysis | Sensory Receptor Cells - physiology | Pain - drug therapy | Bone Neoplasms - physiopathology | Neuralgia - etiology | Pain - etiology | Imidazoles - therapeutic use | Pyridines - therapeutic use | Analgesics - therapeutic use | Receptor, Angiotensin, Type 2 - genetics | Receptor, Angiotensin, Type 2 - biosynthesis | Rats | Imidazoles - pharmacology | Angiotensin II Type 2 Receptor Blockers - therapeutic use | Neuralgia - drug therapy | Ganglia, Spinal - chemistry | Animals | Ganglia, Spinal - pathology | Hyperalgesia - etiology | Neoplasm Proteins - analysis | Prostatic Neoplasms - complications | Pyridines - pharmacology | Care and treatment | Pain | Analgesics | Angiotensin | Nerve growth factor | Prostate cancer | Mitogens
Journal Article
Acta pharmaceutica Sinica. B, ISSN 2211-3835, 2015, Volume 5, Issue 5, pp. 378 - 389
Hypoxia-inducible factor-1(HIF-1) has been recognized as an important cancer drug target.Many recent studies have provided convincing evidences of strong... 
Cancer drug discovery and development | HIF-1α inhibitors | HIF-1α | TRANSCRIPTIONAL ACTIVITY | DNA-BINDING | HIF-1 alpha | PROTEASOMAL DEGRADATION | FACTOR-I | ANTITUMOR-ACTIVITY | SIGNAL-TRANSDUCTION | SMALL-MOLECULE INHIBITORS | TUMOR-SUPPRESSOR PROTEIN | PHARMACOLOGY & PHARMACY | HIF-1 alpha inhibitors | HYPOXIA-INDUCIBLE FACTOR-1 | ENDOTHELIAL GROWTH-FACTOR | RCC, renal cell carcinoma | Ras, rat sarcoma | Raf, rapidly accelerated fibrosarcoma | EGF, epidermal growth factor | C-TAD, COOH-terminal TAD | HTS, high throughput screens | ARD-1, arrest-defective-1 | ELISA, enzyme-linked immunosorbent assay | pVHL, von Hippel-Lindau protein | LEP, leptin | ChIP, chromatin immunoprecipitation | IPAS, inhibitory PAS | IGF-BP3, IGF-factor-binding protein 3 | PAS, Per and Sim | mTOR, mammalian target of rapamycin | RT-PCR, reverse transcription polymerase chain reaction | CAC, circulating angiogenic cells | CoCl2, cobalt chloride | AKt, protein kinase B | TPT, topotecan | bHLH, basic-helix-loop-helix | LDHA, lactate dehydrogenase | GLUTs, glucose transporters | P, proline residue | ODDD, oxygen dependent degradation domain | TGF-α, transforming growth factor α | VEGF, vascular endothelial growth factor | CPTs, camptothecins | Mdm2, mouse double minute 2 homolog | PKM, pyruvate kinase M | AhR, aryl hydrocarbon receptor | K, lysine residue | IGF2, insulin-like growth factor 2 | GLUT3, glucose transporter 3 | CBP associated factor | eIF-4E, eukaryotic translation initiation factor 4E | MEK, MAPK | ADM, adrenomedullin | ARNT, aryl hydrocarbon nuclear translocator | HK2, hexokinase 2 | PHDs, prolyl-4-hydroxylases | PCAF, p300 | FIH-1, factor inhibiting HIF-1 | Review | SIRT 1, Sirtuin 1 | ERK kinase | C-MYC, myelocytomatosis virus oncogene cellular homolog | IGF-BP2, IGF-factor-binding protein 2 | N, asparagine residue | TAD, transactivation domains | HDAC, histone deacetylase | EMSA, electrophoretic mobility shift assay | LRP1, LDL-receptor-related protein 1 | Luc, luciferase | GAs, geldanamycins | HIF-1α, hypoxia-inducible factor-1α | HK1, hexokinase 1 | ID2, DNA-binding protein inhibitor | HPH, HIF-1 prolyl hydroxylases | NOS, nitric oxide synthase | N-TAD, NH2-terminal TAD | MNK, MAP kinase interacting kinase | MTs, microtubules | HRE, hypoxia response elements | ERK, extracellular signal-regulated kinase | EPO, erythropoietin | MAPK, mitogen-activated protein kinases | PI3K, phosphatidyl inositol-4,5-bisphosphate-3-kinase | DFO, deferoxamine | Top I, topoisomerase I | GLUT1, glucose transporter 1 | Hsp90, heat shock protein 90 | TGF-β3, transforming growth factor beta3 | 4E-BP1, eukaryotic translation initiation factor 4E (eIF-4E) binding protein p70 S6 kinase (S6K) | GA, geldanamycin
Journal Article
Genes & cancer, ISSN 1947-6027, 2011, Volume 2, Issue 3, pp. 344 - 358
Somatic, gain-of-function mutations in ras genes were the first specific genetic alterations identified in human cancer about 3 decades ago. Studies during the... 
Mutation | Ras | Ras-MAPK pathway | Oncogenes | Cancer | Developmental syndromes | mutation | developmental syndromes | Monographs | oncogenes | cancer
Journal Article
Journal Article
Biochemical journal, ISSN 1470-8728, 2009, Volume 420, Issue 3, pp. 345 - 361
RTKs (receptor tyrosine kinases) play important roles in cellular proliferation and differentiation. In addition, RTKs reveal oncogenic potential when their... 
Extracellular-signal-regulated kinase (ERK) | Pleiotrophin | Anaplastic large cell lymphoma (ALCL) | Neuroblastoma | Non-small cell lung cancer (NSLCL) | Midkine | Anaplastic lymphoma kinase (ALK) | Inflammatory myofibroblastic tumour (IMT) | ALK PROTEIN EXPRESSION | inflammatory myofibroblastic tumour (IMT) | NPM-ALK | HEPARIN-BINDING | GROWTH-FACTOR PLEIOTROPHIN | non-small cell lung cancer (NSLCL) | BIOCHEMISTRY & MOLECULAR BIOLOGY | anaplastic lymphoma kinase (ALK) | EML4-ALK FUSION GENE | neuroblastoma | LARGE-CELL LYMPHOMA | extracellular-signal-regulated kinase (ERK) | pleiotrophin | NEUROTROPHIC FACTOR HBNF | INFLAMMATORY MYOFIBROBLASTIC TUMOR | NON-HODGKINS-LYMPHOMA | midkine | anaplastic large cell lymphoma (ALCL) | RECEPTOR TYROSINE KINASE | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Oncogene Proteins, Fusion - metabolism | Signal Transduction | Carcinoma, Non-Small-Cell Lung - genetics | Protein-Tyrosine Kinases - metabolism | Humans | Lung Neoplasms - metabolism | Neuroblastoma - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Lung Neoplasms - pathology | Nuclear Proteins - metabolism | Receptor Protein-Tyrosine Kinases | Protein-Tyrosine Kinases - genetics | Models, Biological | Oncogene Proteins, Fusion - genetics | Lymphoma, Large-Cell, Anaplastic - pathology | Neuroblastoma - metabolism | Nuclear Proteins - genetics | Lymphoma, Large-Cell, Anaplastic - metabolism | Neuroblastoma - pathology | Lymphoma, Large-Cell, Anaplastic - genetics | ALK, anaplastic lymphoma kinase | LTK, leucocyte tyrosine kinase | MUC-1, mucin-1 | IRS-1, IR substrate-1 | PTN, pleiotrophin | TGFβ, transforming growth factor β | ERK, extracellular-signal-regulated kinase | PKB, protein kinase B | Shc, Src homology and collagen homology | TPM, tropomyosin | IMP cyclohydrolase | MK, midkine | MYH9, non-muscle myosin heavy chain | MAM, meprin, A5 protein and receptor protein tyrosine phosphatase mu | NPM, nucleophosmin | mTOR, mammalian target of rapamycin | NIPA, nuclear interacting partner of ALK | RPTP, receptor protein tyrosine phosphatase | DLBCL, diffuse large B-cell lymphoma | FOXO3a, forkhead box O 3a | NF-κB, nuclear factor κB | Shp1, SH2 domain-containing phosphatase 1 | RANBP2, Ran-binding protein 2 | ALCL, anaplastic large cell lymphoma | Dpp, decapentaplegic | FRS2, fibroblast growth factor receptor substrate 2 | LDLa, low-density lipoprotein class A | EGFR, epidermal growth factor receptor | SEC31L1, SEC31 homologue A | GIST, gastrointestinal stromal tumour | RTK, receptor tyrosine kinase | SH2, Src homology 2 | TFG, TRK-fused gene | ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase | CLTC, clathrin heavy chain | MAPK, mitogen-activated protein kinase | Hen-1, hesitation-1 | MEK, MAPK | PI3K, phosphoinositide 3-kinase | HEK, human embryonic kidney | SCD-2, suppressor of constitutive dauer 2 | Review | EBPβ, CCAAT | CARS, cysteinyl-tRNA synthetase | JNK, c-Jun N-terminal kinase | ERK kinase | Grb2, growthfactor-receptor-bound protein 2 | SCC, squamous cell carcinoma | EML4, echinoderm microtubule-associated protein like 4 | SHH, sonic hedghog | BCR-Abl, breakpoint cluster region-Abl | IR, insulin receptor | ALO17, ALK lymphoma oligomerization partner on chromosome 17 | enhancer-binding protein β | PLCγ, phospholipase Cγ | NSCLC, non-small cell lung cancer | UCN-01, unco-ordinated 1 | Cdc42, cell division cycle 42 | STAT, signal transducer and activator of transcription | DRG, dorsal root ganglia | MSN, moesin | dALK, Drosophila ALK | IL-3, interleukin-3 | CNS, central nervous system | JAK, Janus kinase | CML, chronic myeloid leukaemia | Jeb, jelly belly | IMT, inflammatory myofibroblastic tumour
Journal Article
Genes & cancer, ISSN 1947-6019, 2011, Volume 2, Issue 3, pp. 359 - 372
Ras genes are frequently activated in cancer. Attempts to develop drugs that target mutant Ras proteins have, so far, been unsuccessful. Tumors bearing these... 
Signal transduction | Ras | Targeted therapy | Raf | MAPK kinase | targeted therapy | signal transduction | Monographs
Journal Article
Biochemical journal, ISSN 1470-8728, 2007, Volume 408, Issue 3, pp. 297 - 315
The specificities of 65 compounds reported to be relatively specific inhibitors of protein kinases have been profiled against a panel of 70-80 protein kinases.... 
Drug discovery | Kinase profiling | Protein kinase | Anti-cancer drugs | Inhibitor specificity | RHO-ASSOCIATED KINASE | TUMOR PROGRESSION | FAMILY-MEMBERS | BIOCHEMISTRY & MOLECULAR BIOLOGY | CELL-PROLIFERATION | protein kinase | P38 MAP KINASE | CYCLIN-DEPENDENT KINASES | RECEPTOR TYROSINE KINASES | drug discovery | kinase profiling | SB 203580 | anti-cancer drugs | ISOFORMS IN-VITRO | P90 RSK | inhibitor specificity | Amino Acid Sequence | Cell Line | Phosphorylation | Recombinant Proteins - antagonists & inhibitors | Animals | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Humans | Drug Design | Protein Kinase Inhibitors - pharmacology | Enzyme Activation | Mitogen-Activated Protein Kinases - metabolism | Spodoptera | Yes1, Yamaguchi sarcoma viral oncogene homologue 1 | CSK, C-terminal Src kinase | Lck, lymphocyte cell-specific protein-tyrosine kinase | EGF, epidermal growth factor | FGF-R, fibroblast-growth-factor receptor | PAK, p21-activated protein kinase | PDK, 3-phosphoinositide-dependent protein kinase | PI3K, phosphatidylinositol (phosphoinositide) 3-kinase | NEK, NIMA (never in mitosis in Aspergillus nidulans)-related kinase | RSK, p90 ribosomal S6 kinase | HEK-293 cells, human embryonic kidney-293 cells | VEGF, vascular endothelial growth factor (vasoendothelial growth factor) | EF2K, elongation-factor-2 kinase | CK, casein kinase | PTEN, phosphatase and tensin homologue deleted on chromosome 10 | ERK, extracellular-signal-regulated kinase | ATM, ataxia telangiectasia mutated | SRPK, serine-arginine protein kinase | IL-1, interleukin 1 | MNK, MAPK-integrating protein kinase | ROCK, Rho-dependent protein kinase | CaMKK, CaMK kinase | GST, glutathione transferase | MKK1, MAPK kinase-1 (also called MEK1, MAPK or ERK kinase 1) | GAK, cyclin G-associated kinase | FMK, fluoromethylketone | MST, mammalian homologue Ste20-like kinase | PKA, cAMP-dependent protein kinase | FKBP, FK506-binding protein | PPAR, peroxisome-proliferator-activated receptor | IKK, inhibitory κB kinase | PH, pleckstrin homology | MBP, myelin basic protein | AICAR, aminoimidazole-4-carboxamide-1-β-D-ribofuranoside | MAPKAP-K, MAPK-activated protein kinase | Sf21, Spodoptera frugiperda (fall armyworm) 21 | MARK, microtubule-affinity-regulating kinase | PIM, provirus integration site for Moloney murine leukaemia virus | LPS, lipopolysaccharide | MSK, mitogen- and stress-activated protein kinase | MAPK, mitogen-activated protein kinase | MELK, maternal embryonic leucine-zipper kinase | His6, hexahistidine | CAK, cyclin-dependent kinase-activating kinase | Eph-A2, Ephrin A2 receptor | PLK, polo-like kinase | ATF2, activating transcription factor 2 | PKD, protein kinase D | Src, sarcoma kinase | AMPK, AMP-activated protein kinase | MMS, methyl methanesulfonate | CHK, checkpoint kinase | JNK, c-Jun N-terminal kinase | TORC1, mTOR (mammalian target of rapamycin)–raptor (regulatory associated protein of mTOR) complex | BRSK, brain-specific kinase | RIP2, receptor-interacting protein 2 | IGF-1, insulin-like growth factor-1 | S6K1, S6 kinase 1 | DYRK, dual-specificity tyrosine-phosphorylated and -regulated kinase | HIPK, homeodomain-interacting protein kinase | ZMP, aminoimidazole-4-carboxamide-1-β-D-ribofuranoside monophosphate | PRAK, p38-regulated activated kinase | PKC, protein kinase C | Src-I1, Src inhibitor 1 | TANK, TRAF (tumour-necrosis-factor-receptor-associated factor)-family-member-associated nuclear factor κB activator | NFAT, nuclear factor for activated T-cells | PHK, phosphorylase kinase | GSK3, glycogen synthase kinase 3 | PKB, protein kinase B (also called Akt) | CaMK, calmodulin-dependent kinase | CDK, cyclin-dependent protein kinase | NDRG, N-myc downstream-regulated gene | SmMLCK, smooth-muscle myosin light-chain kinase | TBK1, TANK-binding kinase 1 | PRK, protein kinase C-related kinase | SGK, serum- and glucocorticoid-induced kinase
Journal Article